Canaanの空売り状況は、投資家がCanaanの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Canaan (NASDAQ:CAN) 株価情報, 空売り情報

Canaan

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

Canaan Inc

Can B Corp

Tema Oncology ETF

Teucrium Sugar Fund ETV

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Cango Inc

CannLabs Inc

Trees Corp

CALIFORNIA NANOTECHS CORP by California Nanotechnologies Corp

California Nanotechnologies Corp

Cano Health Inc Ordinary Shares - Class A

Cano Health Inc Warrants (03/06/2026)

Cian PLC

Calamos Alternative Nasdaq & Bond ETF

CANAQUEST MED CORP by CanaQuest Medical Corporation

CanaQuest Medical Corp

CANARE ELECTRIC CO LTD by CANARE ELECTRIC CO LTD

Canare Electric Co Ltd

WILLOW BIOSCIENCES INC by Willow Biosciences Inc.

Willow Biosciences Inc

CAVENDISH HYDROGEN ASA by CAVENDISH HYDROGEN ASA

Note: The story has been updated to include a comment from a Ford spokesperson.
Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) has reportedly scrapped the development of an advanced electrical architecture that powers modern EVs from the likes of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
What Happened: The company was focused on developing the technology and had invested a lot of resources in developing the project, internally named FNV4, Reuters reported on Thursday, citing three sources familiar with the matter.
However, the increasing costs as well as the delays in development forced the Detroit-based automaker to abandon the project, the report says. The goal for the project was to add more profitable features in both EVs as well as ICE-powered vehicles, and mitigate costs.
A spokesperson for the company told <a href="http://pro.benzinga.com">Benzinga</a> that it&#8217;s not ending the project entirely. Ford is merging two electrical architectures into a single system for all powertrains, bringing connected digital experiences to more vehicles. Key elements of FNV4, like centralized software control and OTA capabilities, are being integrated into this unified platform, the company spokesperson said.
"We are committed to delivering fully connected vehicle experiences across our entire lineup, regardless of powertrain, while many others in the industry are bringing the most advanced tech only to electric vehicles," the spokesperson dded.
&nbsp;A major challenge for companies like Ford is to integrate their complex software with the proprietary computer code from its various suppliers, the report suggests.
If successful, the tech could allow Ford to provide incentives to customers to pay for capabilities like Driver Assistance Systems via OTA updates through subscriptions.
Why It Matters: The report comes in as Ford <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">is gaining ground </a>in the U.S. domestic EV market. The company was one of the top companies in the sector in Q1 2025.
The company also manufactures over 80% of its vehicles in the U.S., which could help the company ride the waves of uncertainty due to the Trump administration's auto tariffs.
Interestingly, Ford recently announced it will <a href="https://www.benzinga.com/25/05/45129156/jim-farley-says-ford-will-delay-price-hike-to-see-how-competitors-react-to-tariffs-extends-employee-pricing-through-july">delay the planned price hike</a> of its vehicles in the U.S. as it continues to work closely with the Trump administration, according to CEO Jim Farley.
The company has <a href="https://www.benzinga.com/25/04/44888445/ford-reportedly-halts-vehicle-shipments-to-china-amid-rising-tariffs">also halted shipments </a>of some of its models to China, in light of the retaliatory tariffs imposed by the CCP on American products, which are as high as 150% in some instances.
Price Action: F currently trades for $10.01 on the NYSE, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45126638/tesla-will-own-the-autonomous-market-dan-ives-says-shrugging-off-waymo-toyota-agreement">Waymo-Toyota Tie-Up A Threat To Elon Musk&#8217;s Tesla? Dan Ives Dismisses It, Says &#8216;No One Can Compete With Their Scale And Scope&#8217;</a></li>
</ul>
Image Via Shutterstock

News

Markets

Tech

General

TSLA

Ford Pulls The Plug On Tesla-like Next Generation Electrical Architecture For EVs And ICE Vehicles: Report (UPDATED)

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) is looking for Q2 GAAP EPS of $0.11-$0.19 vs $0.18 analyst estimate..

Guidance

PRLB

Proto Labs Sees Q2 GAAP EPS $0.11-$0.19 vs $0.18 Est

Full Year 2025 Financial Guidance
For the full year 2025, BrightSpring is increasing guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2024 Revenue and Adjusted EBTIDA results, excluding the Community Living business.
<ul>
<li>Net Revenue of $12,000 million to $12,500 million, or 19.1% to 24.1% growth.
<ul>
<li>Pharmacy Segment Revenue of $10,550 million to $11,000 million, or 20.5% to 25.7% growth.</li>
<li>Provider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth.</li>
</ul>
</li>
<li>Adjusted EBITDA2 of $570 million to $585 million, or 23.9% to 27.2% growth.</li>
</ul>

BTSG

BrightSpring Health Raises FY2025 Sales Guidance from $11.60B-$12.10B To $12.00B-$12.50B Vs $11.96B Est; Sees Adjusted EBITDA Of $570M-$585M

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) is looking for Q2 Adj EPS of $0.30-$0.38 vs $0.33 analyst estimate. sees sales of $124.000 million-$132.000 million vs $126.11 million analyst estimate.

Proto Labs Sees Q2 Adj EPS $0.30-$0.38 vs $0.33 Est; Sees Sales $124.000M-$132.000M vs $126.11M Est

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.29 by 13.79 percent. This is a 17.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $126.20 million which beat the analyst consensus estimate of $123.71 million by 2.02 percent. This is a 1.32 percent decrease over sales of $127.89 million the same period last year.

Earnings

Earnings Beats

Proto Labs Q1 Adj. EPS $0.33 Beats $0.29 Estimate, Sales $126.20M Beat $123.71M Estimate

RDWR

Radware Expands Global Footprint With New Cloud Security Centers In India And Kenya Amid Surge in Web Attacks

DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.95 by 8.42 percent. This is a 30.38 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $3.07 billion which beat the analyst consensus estimate of $3.04 billion by 0.81 percent. This is a 4.61 percent increase over sales of $2.93 billion the same period last year.

DuPont de Nemours Q1 Adj. EPS $1.03 Beats $0.95 Estimate, Sales $3.07B Beat $3.04B Estimate

ENSG

Ensign Group Acquires 117-Bed Marianwood Facility In Washington As Part Of Broader 8-Facility Deal

AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) affirms FY2025 Adj EPS guidance from $2.10-$2.26 to $2.10-$2.26 vs $2.15 analyst estimate..

AES Affirms FY2025 Adj EPS Guidance of $2.10-$2.26 vs $2.15 Est

The Cigna Group's outlook2 for full year 2025 consolidated adjusted income from operations1,2 is $29.60 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2025 dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">(dollars in millions, except where noted and per share amounts)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;2025 Consolidated Metrics</td>
<td colspan="1" rowspan="1">
Projection for Full Year Ending
December 31,&nbsp; 2025
</td>
<td colspan="1" rowspan="1">Change from&nbsp; Prior Projection</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Income from Operations, per share1,2</td>
<td colspan="1" rowspan="1">at least $29.60</td>
<td colspan="1" rowspan="1">+$0.10</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Evernorth Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $7,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $4,125</td>
<td colspan="1" rowspan="1">+$25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Medical Care Ratio2,5</td>
<td colspan="1" rowspan="1">83.2% to 84.2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Cigna Group Raises FY25 Adj EPS Outlook To From At Least $29.50 To At Least $29.60 Vs $29.61 Est

Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) affirms FY2025 Adj EPS guidance from $0.65-$0.70 to $0.65-$0.70 vs $0.68 analyst estimate. Affirms FY2025 sales outlook from $3.00 billion-$3.10 billion to $3.00 billion-$3.10 billion vs $3.03 billion estimate.

AMRX

Amneal Pharmaceuticals Affirms FY2025 Adj EPS Guidance of $0.65-$0.70 vs $0.68 Est; Affirms FY2025 Sales Guidance of $3.00B-$3.10B vs $3.03B Est

AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.46 by 41.3 percent. This is a 46 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $2.93 billion which missed the analyst consensus estimate of $3.10 billion by 5.66 percent. This is a 5.15 percent decrease over sales of $3.08 billion the same period last year.

Earnings Misses

Reported Yesterday, AES Q1 Adj. EPS $0.27 Misses $0.46 Estimate, Sales $2.93B Miss $3.10B Estimate

Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.15 by 40 percent. This is a 50 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $695.42 million which missed the analyst consensus estimate of $715.49 million by 2.80 percent. This is a 5.50 percent increase over sales of $659.19 million the same period last year.

Amneal Pharmaceuticals Q1 Adj. EPS $0.21 Beats $0.15 Estimate, Sales $695.42M Miss $715.49M Estimate

AIRS

AirSculpt Technologies Sees FY2025 Sales $160M-$170M vs $164.05M Est, Adjusted EBITDA Of Approximately $16M-$18M

Patria Declared A Quarterly Dividend Of $0.15 Per Share To Record Holders Of Common Stock At The Close Of Business On May; Dividend Will Be Paid On June 12

Patria Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAX#NASDAQ">PAX</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.25 by 8 percent. This is a 9.52 percent increase over earnings of $0.21 per share from the same period last year.

Patria Investments Q1 Adj. EPS $0.23 Misses $0.25 Estimate

BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.09 by 111.11 percent. This is a 58.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $2.88 billion which beat the analyst consensus estimate of $2.74 billion by 4.90 percent. This is a 11.68 percent increase over sales of $2.58 billion the same period last year.

BrightSpring Health Q1 Adj. EPS $0.19 Beats $0.09 Estimate, Sales $2.88B Beat $2.74B Estimate

AirSculpt Technologies Q1 2025 Adj. EPS $(0.02) Beats $(0.03) Estimate, Sales $39.37M Beat $39.25M Estimate

City Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIO#NYSE">CIO</a>) affirms FY2025 FFO guidance from $1.10-$1.14 to $1.10-$1.14 vs $1.11 analyst estimate..

City Office REIT Affirms FY2025 FFO Guidance of $1.10-$1.14 vs $1.11 Est

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) reported quarterly earnings of $6.74 per share which beat the analyst consensus estimate of $6.35 by 6.14 percent. This is a 4.17 percent increase over earnings of $6.47 per share from the same period last year. The company reported quarterly sales of $65.45 billion which beat the analyst consensus estimate of $60.39 billion by 8.39 percent. This is a 14.33 percent increase over sales of $57.25 billion the same period last year.

Cigna Group Q1 Adj. EPS $6.74 Beats $6.35 Estimate, Adj. Sales $65.45B Beat $60.39B Estimate

Press Releases

Canaan Inc. Announces February 2025 Bitcoin Production, Mining Operation Updates, and Preliminary Fourth Quarter 2024 Financial Results

Canaan Inc. Enters into Securities Purchase Agreement for Series A-1 Preferred Shares Financing and Completes First Tranche Closing

Canaan Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 26, 2025

Contracts

Canaan Inc. Expands Self-Mining Footprint in North America

Canaan Inc. Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

Financing

Mawson Infrastructure Group Inc. Executes New Customer Agreement with Canaan Inc., Growing and Expanding Digital Colocation Business with Latest-Gen ASICs

Comments

Canaan

空売り

Canaan (NASDAQ:CAN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル